Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Gastroenterology. 2019 May;156(6):1753-1760.e1. doi: 10.1053/j.gastro.2019.01.267. Epub 2019 Feb 14.
BACKGROUND & AIMS: Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP). Rectal administration of nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the incidence of post-ERCP pancreatitis (PEP). Little is known about the combined effects of sublingual nitrate and NSAIDs. We performed a randomized trial to assess whether the combination of NSAIDs and sublingual nitrate is more effective than NSAIDs alone in preventing PEP.
In a prospective superiority trial, eligible patients underwent ERCP at 12 endoscopic units in Japan, from March 2015 through May 2018. Patients were randomly assigned to groups given diclofenac suppositories (50 mg) within 15 minutes after the endoscopic procedure alone (diclofenac-alone group, n = 442) or in combination with sublingual isosorbide dinitrate (5 mg) 5 minutes before the endoscopic procedure (combination group, n = 444). The primary endpoint was the occurrence of PEP.
PEP developed in 25 patients in the combination group (5.6%), and in 42 patients in the diclofenac-alone group (9.5%) (relative risk 0.59; 95% confidence interval 0.37-0.95; P = .03). Moderate to severe pancreatitis developed in 4 patients (0.9%) in the combination group, and 10 patients (2.3%) in the diclofenac-alone group (relative risk 0.12; 95% confidence interval 0.13-1.26; P = .12). There was no serious adverse event related to the additional administration of sublingual nitrate.
In a randomized controlled trial, we found that prophylaxis with rectal diclofenac and sublingual nitrate significantly reduces the overall incidence of PEP compared with diclofenac suppository alone. ClinicalTrials.gov, no: UMIN 000016274.
内镜逆行胰胆管造影术(ERCP)的主要不良事件是急性胰腺炎。直肠给予非甾体抗炎药(NSAIDs)可降低 ERCP 后胰腺炎(PEP)的发生率。关于舌下硝酸盐和 NSAIDs 的联合作用知之甚少。我们进行了一项随机试验,以评估 NSAIDs 和舌下硝酸盐的联合应用是否比单独使用 NSAIDs 更能预防 PEP。
在一项前瞻性优效性试验中,符合条件的患者于 2015 年 3 月至 2018 年 5 月在日本的 12 个内镜单位接受 ERCP。患者被随机分配至接受直肠给予双氯芬酸钠栓剂(50mg)组(n=442)或在 ERCP 前 5 分钟给予直肠给予双氯芬酸钠栓剂(50mg)联合舌下给予硝酸异山梨酯(5mg)组(n=444)。主要终点是 PEP 的发生。
联合组 25 例(5.6%)和双氯芬酸钠单独组 42 例(9.5%)发生 PEP(相对风险 0.59;95%置信区间 0.37-0.95;P=0.03)。联合组 4 例(0.9%)和双氯芬酸钠单独组 10 例(2.3%)发生中度至重度胰腺炎(相对风险 0.12;95%置信区间 0.13-1.26;P=0.12)。舌下给予硝酸异山梨酯无严重不良事件。
在一项随机对照试验中,我们发现与单独使用直肠给予双氯芬酸钠栓剂相比,直肠给予双氯芬酸钠栓剂和舌下给予硝酸异山梨酯可显著降低 PEP 的总发生率。临床试验.gov,编号:UMIN 000016274。